therapeutic cloning and induced pluripotent stem cells

Additionally, the use of patient-specific iPSCs offers the possibility of personalized medicine. iPSCs have several advantages due to their human origin, ability to expand in culture, accessibility, and ability to differentiate into virtually any desired cell type. However, ethical and safety concerns regarding ESCs have long impeded their applications, and the development of iPSCs technology appears to address these concerns. Recent human embryonic stem cells (ESCs) applications have introduced a novel approach to cancer research. The iPSCs technology developed in recent years is anticipated to enhance traditional models. Traditional models have been an essential tool in cancer research however, they have limitations, including a lack of heterogeneity, low efficiency, and difficulty simulating cancer progression.

Researchers have spent many years studying the development and pathogenesis of malignant solid tumors to improve treatments. Additionally, therapies, including drugs, radiotherapy, and chemotherapy have unpleasant side effects that exacerbate patients' discomfort. Malignant solid tumors are difficult to treat thoroughly with conventional treatments due to incomplete local resection, metastasis, invasion, drug resistance, and recurrence. Additionally, we discuss potential obstacles to induced pluripotent stem cell technology. This review summarizes the evolution of induced pluripotent stem cells technology and its applications in malignant solid tumor. Induced pluripotent stem cells derived from somatic cells, cancer cell lines, primary tumors, and individuals with an inherited propensity to develop cancer have shown great potential in cancer modeling, cell therapy, immunotherapy, and understanding tumor progression. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from modeling to treatment. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors.

Therapeutic cloning and induced pluripotent stem cells